What is CardioMech?
CardioMech is a medical technology innovator dedicated to the development of advanced therapeutic solutions for structural heart disease. Its primary focus is the CardioMech MVRS, a transcatheter mitral valve repair system designed to provide a less invasive alternative to conventional open-heart surgery. By targeting both surgical and non-surgical patient populations, the company aims to simplify complex cardiac procedures and improve patient outcomes. Currently, the firm operates within the investigational stage, prioritizing rigorous clinical validation of its proprietary device to ensure safety and efficacy before commercial deployment. The company's market position is defined by its commitment to reducing the procedural burden associated with mitral valve repair, a condition that remains a significant challenge in modern cardiology.
How much funding has CardioMech raised?
CardioMech has raised a total of $36.5M across 3 funding rounds:
Debt
$5M
Series A
$18.5M
Other Financing Round
$13M
Debt (2019): $5M, investors not publicly disclosed
Series A (2020): $18.5M led by Hadean Ventures and Investinor
Other Financing Round (2024): $13M, investors not publicly disclosed
Key Investors in CardioMech
Investinor
Investinor AS is an investment company that collaborates with entrepreneurs, startups, and other investors to develop selected promising businesses into world leaders. The company manages a significant investment portfolio, with a focus on sustainable investments and innovation.
Hadean Ventures
A venture capital firm specializing in early-stage life science and biotech investments, focusing on companies with high-impact medical technologies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for CardioMech?
With the recent influx of capital, CardioMech is well-positioned to accelerate its clinical trial roadmap and refine its transcatheter delivery systems. The strategic focus will likely shift toward navigating regulatory pathways and expanding the evidence base for the MVRS device. As the company transitions from early-stage development to more advanced investigational milestones, the primary objective remains the successful demonstration of clinical superiority over existing surgical standards. Future growth will depend on the company's ability to maintain its technological edge while scaling its operational capabilities to meet the rigorous demands of the global cardiovascular device market.
See full CardioMech company page
